According to a company report, Ryvu Therapeutics recorded a PLN 24.24m standalone net loss from continuing operations in the second quarter of 2021. This is higher than last year when the loss amounted to PLN 4.3m. The company also suffered a higher operating loss and EBITDA loss from continuing operations than in 2020. Ryvu Therapeutics…
Ryvu Therapeutics S.A., one of Europe’s largest innovative biotechnology companies active in the discovery and development of new oncology therapies, has announced that Vatnak Vat-Ho is joining the company as Chief Business Officer. Ryvu will gain knowledge and experience from Vatnak Vat-Ho Vatnak Vat-Ho holds a bachelor’s degree in biology from Harvard University. Ryvu‘s new…
Ryvu Therapeutics (formerly Selvita), a Polish biotechnology company, is expanding its plans for R&D projects. By the end of 2022, the company intends to have at least three projects in the clinical phase. SEL120 in Phase II in two years’ time The key drug in Ryvu’s portfolio is SEL120, designed to treat acute myelogenous leukemia…
Selvita, which specialises in laboratory research and development services for external customers, wants to increase the scale of its operations in the near future. This will be achieved, among other things, through acquisitions. The first transaction is to be finalised in 2020, Puls Biznesu reports. Purchase of competence and access to customers After separating the…
The last few days have brought a lot of changes in the biotechnological company Selvita. The company’s shareholders agreed to split the company and appoint four new members of the supervisory board of Ryvu Therapeutics. Selvita also announced the launch of phase I clinical trials of its acute myeloid leukemia drug (SEL120). Selvita separates Ryvu…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.